Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease

Table 1 Summary of key trials assessing sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

Trial	SGLT2i	Population	Results (primary outcome)
CREDENCE[86]	Canagliflozin (100 mg)	Patients with T2D; eGFR 30-90 mL/minute and uACR > 300 to 5000 mg/g	↓Evolution to ESKD; ↓death from cardiovascular causes
DAPA-CKD[85]	Dapagliflozin (10 mg)	Regardless of T2D status; eGFR 25-75 mL/minute and uACR > 200 to 5000 mg/g	↓Sustained decline of eGFR of 50% or more; ↓evolution to ESKD
SCORED[88]	Sotagliflozin (200-400 mg)	Patients with T2D; eGFR 25-50 mL/minute (regardless of albuminuria); an additional CVD risk factor	↓Hospitalization and urgent visits due to heart failure
EMPA-KIDNEY[89]	Empagliflozin (10 mg)	Patients with and without T1D or T2D; eGFR 20-45 mL/minute (regardless of albuminuria); or eGFR 45-90 mL/minute (with uACR > 200 mg/g)	↓Progression of kidney disease

eGFR: Estimated glomerular filtration rate; uACR: Urinary albumin-to-creatinine ratio; T1D: Type 1 diabetes; T2D: Type 2 diabetes; CVD: Cardiovascular disease; SGLT2i: Sodium-glucose cotransporter 2 inhibitor; ESKD: End-stage kidney disease; CKD: Chronic kidney disease.